ACAN Vaccinia Immunoglobulin intravenous (human) - VIGIV
Public summary
Generated or condensed from imported source text. Verify before bidding.
This is an open Advanced Contract Award Notice (ACAN) from Public Services and Procurement Canada (PSPC), on behalf of the Public Health Agency of Canada (PHAC), for Vaccinia Immunoglobulin Intravenous (Human), or VIGIV. PHAC needs this product to help protect against complications associated with live-replicating smallpox vaccines containing vaccinia virus. PSPC intends to negotiate the contract with the pre-identified supplier, Emergent Bio Solutions Canada Inc. Other suppliers are not being invited to submit a standard bid at this stage, but may challenge the proposed award by submitting a statement of capabilities showing that they can meet the stated requirement. If no capable alternative supplier responds by the deadline, PSPC may proceed with the proposed contract award. The notice is listed for Canada, with Gatineau, Quebec shown as the location, and closes September 30, 2026 at 2:00 p.m. The time zone and full submission requirements should be confirmed in the official notice. This opportunity appears potentially relevant mainly to suppliers that can provide the specified VIGIV product and meet PHAC’s technical, regulatory, supply, and delivery requirements. A company should not assume it qualifies based on this summary alone. Review the complete ACAN and submit any statement of capabilities through the required process before the closing date if appropriate: https://portal.us.bn.cloud.ariba.com/dashboard/public/appext/comsapsbncdiscoveryui#/Rfx Event/preview/1110024564?an Id=ANONYMOUS. Always verify the official tender notice for the authoritative requirements, deadlines, and submission instructions before responding.
Requirement preview
A profile unlocks the full bid checklist and match explanation.
- This is an Advanced Contract Award Notice (ACAN), not a standard open bid. Other suppliers may submit a statement of capabilities to demonstrate that they meet the stated requirement.
- A statement of capabilities must be submitted on or before the closing date of September 30, 2026, at 14:00:00. The tender text does not specify the submission method or time zone; these details should be verified in the official notice.
- The requirement is for Vaccinia Immunoglobulin intravenous (human) (VIGIV).
- The product is intended to protect against complications from vaccination with live-replicating smallpox vaccines containing vaccinia virus.
Source description preview
Imported source text may contain formatting from the original notice.
Advanced Contract Award Notice(ACAN) - Vaccinia Immunoglobulin intravenous (human) (VIGIV) An ACAN is a public notice indicating to the supplier community that a department or agency intends to award a contract for goods, services or construction to a pre-identified supplier, thereby allowing other suppliers to signal their interest in bidding, by submitting a statement of capabilities. If no supplier submits a statement of capabilities that meets the requirements set out in the ACAN, on or before the closing date stated in the ACAN, the contracting officer may then proceed with the award to the pre identified supplier. Purpose of this Advanced Contract Award Notice (ACAN): Public Services and Procurement Canada proposes to negotiate a contract with Emergent Bio Solutions Canada Inc on behalf of Public Health Agency of Canada (PHAC).Requirement description: Public Health Agency of Canada (PHAC) has a requirement for vaccinia Immunoglobulin intravenous (human) (VIGIV) to protect against complications from vaccination with live-replicating smallpox vaccines containing vaccinia virus.
Turn this listing into a bid decision.
Build a company profile to unlock match scoring, explanations, checklist next steps, saved opportunity tracking, and alerts.